The present invention relates to a new pharmaceutical composition for viral immunotherapy, and in particular, a pharmaceutical composition for viral immunotherapy for persistent hepatitis B infection. The present pharmaceutical composition consists of an antiviral agent, an immunomodulatory agent and a recombinant hepatitis B vaccine, and is used for treating hepatitis B, in particular chronic hepatitis B. In the present pharmaceutical composition, the antiviral agent is selected from ±-IFN, nucleoside analogues, and the like, and the immunomodulatory agent is selected from GM-CSF and the like.
